Valuation : Paion

Market Cap 1L 2L 1L 1L 2L 1.6Cr 2L 16.2L 6L 81.27L 6L 6L 2.59Cr P/E 2021
-3.89x
P/E 2022 -53x
Enterprise Value 98.67L 1.15Cr 93.15L 84.79L 1.58Cr 109.36Cr 1.6Cr 11Cr 4.27Cr 56Cr 4.3Cr 4.21Cr 177.01Cr EV / Sales 2021
14.1x
EV / Sales 2022 1.22x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 week+4.35%
Current month+4.35%
1 month+3.23%
3 months-10.28%
6 months-27.27%
Current year+263.64%
1 week 0.05
Extreme 0.046
0.05
1 month 0.04
Extreme 0.044
0.05
3 years 0
Extreme 0.0001
4.82
5 years 0
Extreme 0.0001
18.22
10 years 0
Extreme 0.0001
34.75
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2023
Director of Finance/CFO - 01/06/2022
Director TitleAgeSince
Director/Board Member 65 01/10/2012
Director/Board Member 75 01/06/2017
Director/Board Member - 22/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.35%+433.33%-99.04% 4L
-0.56%-8.30%-5.88%+10.58% 4.64TCr
-2.08%-2.81%+396.70%+533.09% 4.45TCr
+0.12%-2.48%+35.68%+20.50% 4.23TCr
-2.62%-5.52%-2.66%+77.44% 3.99TCr
-1.26%-2.95%+12.00%+40.55% 3.28TCr
+0.16%-2.27% - - 1.71TCr
-0.54%-1.66%+20.09%+115.10% 1.64TCr
-0.03%-2.56%+10.88%+30.90% 1.43TCr
-1.92%-6.43%+73.47%+36.68% 1.33TCr
Average -0.97%-3.08%+108.18%+85.09% 2.97TCr
Weighted average by Cap. -1.09%-3.25%+82.62%+129.36%

Financials

2021 2022
Net sales 71.28L 82.75L 67.3L 61.25L 1.14Cr 79Cr 1.16Cr 8.01Cr 3.08Cr 40Cr 3.11Cr 3.04Cr 127.88Cr 3.32Cr 3.86Cr 3.14Cr 2.86Cr 5.34Cr 368.48Cr 5.39Cr 37Cr 14Cr 187.51Cr 14Cr 14Cr 596.44Cr
Net income -2.18Cr -2.53Cr -2.06Cr -1.87Cr -3.5Cr -241.45Cr -3.53Cr -24Cr -9.42Cr -122.86Cr -9.5Cr -9.29Cr -390.82Cr -6L -7L -5L -5L -9L -6.42Cr -9L -65.1L -25.04L -3.27Cr -25.24L -24.69L -10Cr
Net Debt 1.38Cr 1.6Cr 1.3Cr 1.18Cr 2.21Cr 152.6Cr 2.23Cr 15Cr 5.95Cr 78Cr 6Cr 5.87Cr 247.01Cr 97.23L 1.13Cr 91.79L 83.55L 1.56Cr 107.76Cr 1.58Cr 11Cr 4.2Cr 55Cr 4.24Cr 4.15Cr 174.42Cr
Logo Paion
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Employees
-
Date Price Change
10/26/10 €0.0480 0.00%
09/26/09 €0.0480 +4.35%
08/26/08 €0.0460 0.00%
07/26/07 €0.0460 0.00%
04/26/04 €0.0460 0.00%
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!